During treatment with inhaled beclomethasone the osteocalcin concentrations decreased, as has been observed in patients taking oral corticosteroids. This might imply that during beclomethasone treatment bone formation is depressed, which could result in osteoporosis in the long run.
Comment
During treatment with inhaled beclomethasone the osteocalcin concentrations decreased, as has been observed in patients taking oral corticosteroids. This might imply that during beclomethasone treatment bone formation is depressed, which could result in osteoporosis in the long run.
In our pilot study we investigated healthy subjects who used a high dose of beclomethasone for a short period of time. Whether osteocalcin concentrations are also lowered in asthmatic patients treated with lower doses ofbeclomethasone over the long term is unknown at present. This is not unlikely, however-firstly, because the resorption of the drug might be better in patients than in healthy subjects and, secondly, because osteocalcin remained depressed during long term treatment of patients with oral corticosteroids.4 Therefore a longitudinal study measuring serum osteocalcin concentrations and bone mineral density in newly diagnosed patients with asthma taking inhaled corticosteroids seems warranted.
We thank Mrs W Norder-Paulides for technical assistance. Methods and results Using radioimmunoassay, we measured serum thyroid stimulating hormone, free and total thyroxine, and triiodothyronine concentrations in umbilical venous blood samples obtained by cordocentesis from 15 fetuses with chromosomal abnormalities (trisomy 21 (five), trisomy 18 (five), trisomy 13 (one), triploidy (two), and Klinefelter's syndrome (two)) at 17-36 weeks' gestation.34 The indication for cordocentesis was fetal karyotyping after fetal malformations had been detected by ultrasonography. Informed consent was obtained from the mothers, and the project was approved by the hospital ethical committee.
In the five fetuses with Down's syndrome, two of the five with trisomy 18, and one of the two with triploidy thyroid stimulating hormone concentration was above the 95th centile of the reference range ( figure) . In all 15 fetuses, however, thyroid hormone concentrations were within the reference ranges, and the mean values were not significantly different from the normal means for gestation (free triiodothyronine concentration: mean difference=0 118 SD, t=0-30; free thyroxine: -0 249 SD, t=0 61; total triiodothyronine: 0 705 SD, t=2 87; total thyroxine: 0 225 SD t=0 56).
The high thyroid stimulating hormone in some fetuses with a chromosomal abnormality, particularly those with trisomy 21, may be an early manifestation of relative hypothyroidism. Animal studies have In humans congenital hypothyroidism is associated with appreciable abnormalities in physical and neurological development, manifested at its extreme by cretinism. Prompt postnatal treatment usually prevents these adverse sequelae. Intrauterine hypothyroidism of early onset, as documented in some fetuses with chromosomal abnormalities, could, however, result in irreversible brain damage and may be one of the underlying causes of mental handicap in such infants. The extent to which intrauterine hormone supplementation would reduce impaired neurological development remains to be determined.
